secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0000950170-21-003727
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux reports Q3 net loss of $10.8M, cash $387.5M; IND filings on track for 2022
--------------------------------------------------------------------------------

- Cash and equivalents $387.5M at Sept 30, 2021, up from $7.8M at Dec 31, 2020.
- R&D expenses $8.4M (vs $0.8M in Q3 2020); G&A $3.6M (vs $0.4M).
- PSMA-TRACTr IND submission expected H1 2022; EGFR-TRACTr IND expected H2 2022.
- TRACIr costimulatory bispecific candidate selection planned in 2022.
- Board strengthened with appointments of Ron Barrett (Ph.D.) and Alana McNulty.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017021003727/0000950170-21-003727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017021003727/janx-20211109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-003727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer